{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T13:22:51Z","timestamp":1648905771259},"reference-count":19,"publisher":"BMJ","license":[{"start":{"date-parts":[[2018,10,25]],"date-time":"2018-10-25T00:00:00Z","timestamp":1540425600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.bmj.com\/company\/legal-information\/terms-conditions\/legal-information\/tdm-licencepolicy"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ"],"DOI":"10.1136\/bmj.k4203","type":"journal-article","created":{"date-parts":[[2018,10,25]],"date-time":"2018-10-25T17:10:04Z","timestamp":1540487404000},"page":"k4203","update-policy":"http:\/\/dx.doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Which shingles vaccine for older adults?"],"prefix":"10.1136","author":[{"given":"Phuc","family":"Le","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2018,10,25]]},"reference":[{"key":"key20190314145725_ref1","unstructured":"GlaxoSmithKline. Shingrix approved in the US for prevention of shingles in adults aged 50 and over-Pooled clinical trial results showed > 90 percent efficacy across all age groups. 2017; http:\/\/us.gsk.com\/en-us\/media\/press-releases\/2017\/shingrix-approved-in-the-us-for-prevention-of-shingles-in-adults-aged-50-and-over\/. Accessed September 28, 2018."},{"key":"key20190314145725_ref2","unstructured":"GlaxoSmithKline. SHINGRIX approved in Canada as the first non-live adjuvanted vaccine to help protect against shingles. 2017; http:\/\/ca.gsk.com\/en-ca\/media\/press-releases\/2017\/shingrix-approved-in-canada-as-the-first-non-live-adjuvanted-vaccine-to-help-protect-against-shingles\/. Accessed September 28, 2018."},{"key":"key20190314145725_ref3","unstructured":"GlaxoSmithKline. Shingrix approved in Europe and Japan for the prevention of shingles in adults aged 50 and over-The only shingles vaccine to achieve \u226590% efficacy across all age groups studied. 2018; www.gsk.com\/en-gb\/media\/press-releases\/shingrix-approved-in-europe-and-japan-for-the-prevention-of-shingles-in-adults-aged-50-and-over\/#_edn1. Accessed September 28, 2018."},{"key":"key20190314145725_ref4","doi-asserted-by":"crossref","first-page":"k4029","DOI":"10.1136\/bmj.k4029","article-title":"Efficacy, effectiveness, and safety of herpes zoster vaccines in adults aged 50 and older: systematic review and network meta-analysis","volume":"636","author":"Tricco","year":"2018","journal-title":"BMJ"},{"key":"key20190314145725_ref5","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6703a5"},{"key":"key20190314145725_ref6","unstructured":"An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI). Updated Recommendations on the Use of Herpes Zoster Vaccines. Public Health Agency of Canada. Government of Canada;2018."},{"key":"key20190314145725_ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.01.019"},{"key":"key20190314145725_ref8","unstructured":"Centers for Disease Control and Prevention. Current Vaccine Shortage &Delays. https:\/\/www.cdc.gov\/vaccines\/hcp\/clinical-resources\/shortages.html. Accessed September 28, 2018."},{"key":"key20190314145725_ref9","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2018.3200"},{"key":"key20190314145725_ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603800"},{"key":"key20190314145725_ref11","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.vaccine.2017.11.019","article-title":"Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: Results of a phase III, randomized, open-label, multicenter study","volume":"36","author":"Lal","year":"2018","journal-title":"Vaccine"},{"key":"key20190314145725_ref12","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2016.1154247"},{"key":"key20190314145725_ref13","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6720a4"},{"key":"key20190314145725_ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501184"},{"key":"key20190314145725_ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051016"},{"key":"key20190314145725_ref16","unstructured":"Centers for Disease Control and Prevention. Vaccination Coverage Among Adults in the United States, National Health Interview Survey, 2016. 2018; https:\/\/www.cdc.gov\/vaccines\/imz-managers\/coverage\/adultvaxview\/pubs-resources\/NHIS-2016.html. Accessed 9-27, 2018."},{"key":"key20190314145725_ref17","unstructured":"Public Health England. Shingles vaccine coverage report, England, February to May 2018. Health Protection Report. Vol 12 Number 27."},{"key":"key20190314145725_ref18","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1186\/1471-2458-14-1098","article-title":"Herpes zoster vaccine (HZV): utilization and coverage 2009 - 2013, Alberta, Canada","volume":"14","author":"Liu","year":"2014","journal-title":"BMC Public Health"},{"key":"key20190314145725_ref19","unstructured":"Centers for Disease Control and Prevention. Adult vaccine price list (Accessed at http:\/\/www.cdc.gov\/vaccines\/programs\/vfc\/awardees\/vaccine-management\/price-list\/ on Sept 28, 2018). 2018."}],"container-title":["BMJ"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/data.bmj.org\/tdm\/10.1136\/bmj.k4203","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmj.k4203","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T00:51:55Z","timestamp":1601081515000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.bmj.com\/lookup\/doi\/10.1136\/bmj.k4203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,25]]},"references-count":19,"alternative-id":["10.1136\/bmj.k4203"],"URL":"https:\/\/doi.org\/10.1136\/bmj.k4203","relation":{},"ISSN":["0959-8138","1756-1833"],"issn-type":[{"value":"0959-8138","type":"print"},{"value":"1756-1833","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,25]]}}}